BiiodicA leading world CDMO, expands his congratulations to Junshi Biosciences (HKEX-1877, SSE-688180), to receiving the approval of new drugs (ind) from China’s National Medical Products Administration (NMPA) for JS212, a Bispecific-Drug Conjuch (ADC) for The target both EGFR and Her-Reptors’ s Moders.
JS212 represents a new category of diplomatic ADCs combining the humanized epidermal growth factor and the human epidermal riming factor of 3-disc antibodies conjugated to target both EGFR and HER3. of the lung, breast cancer and head cancer. As an ADC, JS212 has a key advantage over traditional ADCs that target only one protein: it can attack tumors through either EGFR or HER3, possibly increasing its effectiveness over a wider range of cancers and helping to treat drug resistance.
“As a leader in ADC technology, Biodlink remains committed to technological innovation and a soluble solution for a soluble solution for complex biologically. Promoting this important program.”
Dr. Jun Liu, Managing Director and Executive Director of Biodlink
“We are very pleased with continuing and extremely productive collaboration with Biodlink. Their excellent expertise and proven opportunities in the development and construction of ADC played a central role in promoting JS212 in this important milestone. I look forward to deepening our collaboration as we work.
Dr. Jing Tong, Deputy Director of Junshi Biosciences Institute of Innovation Research
Biodlink is a reliable biological CDMO partner, operating a large -scale website, with integrated production lines dedicated to antibodies and ADCs. ADC’s integrated platform, supported by advanced R&D capabilities, allows central and effective production of intermediate antibodies, medicines and finished products – accelerating timetables, minimizing the cost of transporting technology and the fulfillment of strict GMP global standards.
